Bristol Myers Squibb licenses cell therapy candidate from Obsidian
Bristol Myers Squibb has exercised an option to an exclusive worldwide license to a cell therapy candidate based on Obsidian Therapeutics' cytoDrive technology. Read More
Hexagon Bio secures $47M to advance drug discovery platform
Hexagon Bio has closed $47 million in series A financing to advance its drug discovery capabilities on its fungal genomics-based platform. Read More
Sherlock launches nonprofit to promote equity, STEM during COVID-19
Sherlock Biosciences has formed the 221b Foundation, a nonprofit organization committed to assisting in the eradication of COVID-19, while supporting racial and gender diversity in STEM. Read More
Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with its deep cell characterization capabilities. These efforts are highlighted by the rapid impact that Berkeley Lights' Beacon systems had during the early days of the COVID-19 pandemic. Read More
Neogene Therapeutics to develop personalized cell therapies
Neogene Therapeutics is pioneering a new class of fully personalized neoantigen T-cell therapies to treat cancer supported by $110 million in series A financing. Read More
Neurocrine, Voyager tout gene therapy clinical results for Parkinson's disease
Neurocrine Biosciences and Voyager Therapeutics have released data from a phase Ib open-label, three-year efficacy and safety study of NBIb-1817, an investigational gene therapy to improve motor function in patients with Parkinson's disease. Read More
Making CRISPR safer with new enzyme-based prediction tool
A new technique will help scientists choose the best available gene editing option for any given indication, making CRISPR technology safer, cheaper, and more effective. The tool is outlined in a September 7 article in Nature Biotechnology. Read More
Atara advances CAR T technology with IND clearance
Atara Biotherapeutics said that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ATA2271, a next-generation, autologous mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with advanced mesothelioma. Read More
Canbridge, UMass partner on gene therapies for neuromuscular diseases
Canbridge Pharmaceuticals has expanded its gene-therapy partnership with the University of Massachusetts (UMass) Medical School. Read More
Customized gene therapies successfully target rare eye diseases
Can gene therapies prove effective for the treatment of rare genetic diseases? One company may have found a solution that incorporates a high degree of customization, manufacturing expertise, and years' worth of knowledge. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter